{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T11:32:47Z","timestamp":1774611167204,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T00:00:00Z","timestamp":1590710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Little is reported on the real\u2010life impact of daratumumab in relapsed and\/or refractory multiple myeloma patients (RRMM). We analyzed a cohort of 156 patients who received daratumumab as a single agent concerning ECOG status, eGFR, cytogenetics, lines of prior treatment, and their impact on survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty\u2010two (53%) patients were triple refractory, 54 (35%) patients were single or double refractory, and 20 (12%) patients were non\u2010refractory. Following daratumumab treatment, the progression\u2010free survival (PFS) in these groups was 7.2%, 11.4%, and 53% (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), and overall survival (OS) was 34%, 73%, and 58% (<jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001) at 36\u00a0months, respectively. Poor ECOG, three lines of prior treatment, and triple refractoriness were all associated with inferior PFS and OS in a multivariate analysis including ECOG, high\u2010risk chromosomal aberrations, refractoriness, number of treatment lines, and eGFR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Daratumumab remains an attractive treatment option, especially in patients with poor performance and increased frailty. Furthermore, our observations suggest that patients with ECOG 2 and 3 status require additional supportive and\/or palliative therapies to compensate for a potentially effective but encompassing late\u2010line therapy. In conclusion, further prospective studies are needed to elucidate the impact of ECOG 2 and 3 status in patients with RRMM.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.13426","type":"journal-article","created":{"date-parts":[[2020,4,13]],"date-time":"2020-04-13T06:05:35Z","timestamp":1586757935000},"page":"196-202","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Impact of performance status on overall survival in patients with relapsed and\/or refractory multiple myeloma: Real\u2010life outcomes of daratumumab treatment"],"prefix":"10.1111","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7376-535X","authenticated-orcid":false,"given":"Garbriel","family":"Afram","sequence":"first","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6069-6615","authenticated-orcid":false,"given":"Charlotte","family":"Gran","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-311X","authenticated-orcid":false,"given":"Johanna","family":"Borg Bruchfeld","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-8259","authenticated-orcid":false,"given":"Arnika Kathleen","family":"Wagner","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alamdar","family":"Hussain","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evren","family":"Alici","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hareth","family":"Nahi","sequence":"additional","affiliation":[{"name":"Karolinska Institutet Department of Medicine Huddinge Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,5,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12465"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0681-6"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","unstructured":"MadduriD.Results from CARTITUDE\u2010a: A Phase 1b\/2 Study of JNJ\u20104528 a CAR\u2010T Cell Therapy Directed Against B\u2010Cell Maturation Antigen (BCMA) in Patients with Relapse and\/or Refractory Multiple Myeloma (R\/R MM). 61st American Society of Hematology annual meeting and exposition.2019;Oral abstract #577.","DOI":"10.1182\/blood-2019-121731"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","unstructured":"WangBY.Long\u2010Term Follow\u2010up of a Phase 1 First\u2010in\u2010Human Open\u2010Label Study of LCAR\u2010B38; a Structurally Differentiated Chimeric Antigen Receptor T (CAR\u2010T) Cell Theraphy Targeting B\u2010Cell Maturation Antigen (BCMA) in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM). 61st American Society of Hematology annual meeting and exposition.2019;Oral ABstract 579.","DOI":"10.1182\/blood-2019-124953"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.291"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0713-4"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.217448"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13712"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.13426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13426","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.13426","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.13426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T16:27:27Z","timestamp":1693931247000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.13426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,29]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1111\/ejh.13426"],"URL":"https:\/\/doi.org\/10.1111\/ejh.13426","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,29]]},"assertion":[{"value":"2020-03-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-06","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}